The Bill & Melinda Gates Foundation invested $10 million in Liquidia Technologies, a closely held biotechnology company developing vaccines, as part of a $400 million initiative to fund activities to help poorer countries.

Liquidia is developing a seasonal flu vaccine and has an agreement with the PATH Malaria Vaccine Initiative to use its technology to work on new malaria vaccines, the Research Triangle Park, North Carolina-based company said today in an e- mailed statement.

The $400 million program provides low-interest loans, loan guarantees and equity investments to help finance organizations that meet the group’s focus areas.

via Bloomberg.